706 related articles for article (PubMed ID: 18031313)
1. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.
Karavitaki N; Turner HE; Adams CB; Cudlip S; Byrne JV; Fazal-Sanderson V; Rowlers S; Trainer PJ; Wass JA
Clin Endocrinol (Oxf); 2008 Jun; 68(6):970-5. PubMed ID: 18031313
[TBL] [Abstract][Full Text] [Related]
2. Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma.
Li ZQ; Quan Z; Tian HL; Cheng M
J Int Med Res; 2012; 40(2):517-24. PubMed ID: 22613412
[TBL] [Abstract][Full Text] [Related]
3. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
[TBL] [Abstract][Full Text] [Related]
4. [Preoperative administration of a slow releasing somatostatin analog (SR-lanreotide, BIM 23014) in patients with acromegaly in the course of GH-releasing adenoma].
Zieliński G; Podgórski JK; Koziarski A; Siwik J; Zgliczyński W; Wieliczko W
Neurol Neurochir Pol; 2001; 35(3):423-37. PubMed ID: 11732266
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide.
Suliman M; Jenkins R; Ross R; Powell T; Battersby R; Cullen DR
J Endocrinol Invest; 1999 Jun; 22(6):409-18. PubMed ID: 10435849
[TBL] [Abstract][Full Text] [Related]
6. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage.
Lucas T; Astorga R; Catalá M;
Clin Endocrinol (Oxf); 2003 Apr; 58(4):471-81. PubMed ID: 12641631
[TBL] [Abstract][Full Text] [Related]
7. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
Amato G; Mazziotti G; Rotondi M; Iorio S; Doga M; Sorvillo F; Manganella G; Di Salle F; Giustina A; Carella C
Clin Endocrinol (Oxf); 2002 Jan; 56(1):65-71. PubMed ID: 11849248
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma.
Cannavò S; Squadrito S; Curtò L; Almoto B; Trimarchi F
Horm Metab Res; 2001 Oct; 33(10):618-24. PubMed ID: 11607883
[TBL] [Abstract][Full Text] [Related]
10. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
[TBL] [Abstract][Full Text] [Related]
11. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
Verhelst JA; Pedroncelli AM; Abs R; Montini M; Vandeweghe MV; Albani G; Maiter D; Pagani MD; Legros JJ; Gianola D; Bex M; Poppe K; Mockel J; Pagani G
Eur J Endocrinol; 2000 Nov; 143(5):577-84. PubMed ID: 11078980
[TBL] [Abstract][Full Text] [Related]
12. Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial.
Mao ZG; Zhu YH; Tang HL; Wang DY; Zhou J; He DS; Lan H; Luo BN; Wang HJ
Eur J Endocrinol; 2010 Apr; 162(4):661-6. PubMed ID: 20061334
[TBL] [Abstract][Full Text] [Related]
13. Preoperative somatostatin analogs treatment in acromegalic patients with macroadenomas. A meta-analysis.
Zhang L; Wu X; Yan Y; Qian J; Lu Y; Luo C
Brain Dev; 2015 Feb; 37(2):181-90. PubMed ID: 24815226
[TBL] [Abstract][Full Text] [Related]
14. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
[TBL] [Abstract][Full Text] [Related]
15. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly.
al-Maskari M; Gebbie J; Kendall-Taylor P
Clin Endocrinol (Oxf); 1996 Oct; 45(4):415-21. PubMed ID: 8959079
[TBL] [Abstract][Full Text] [Related]
16. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
17. Results of a two-year treatment with slow release lanreotide in acromegaly.
Cannavò S; Squadrito S; Curtò L; Almoto B; Vieni A; Trimarchi F
Horm Metab Res; 2000 Jun; 32(6):224-9. PubMed ID: 10898551
[TBL] [Abstract][Full Text] [Related]
18. [Outcome of somatostatin analogue treatment in acromegaly].
Mondok A; Tóth M; Patócs A; Szücs N; Igaz P; Pusztai P; Czirják S; Beko G; Gláz E; Rácz K; Tulassay Z
Orv Hetil; 2009 Aug; 150(31):1457-62. PubMed ID: 19617182
[TBL] [Abstract][Full Text] [Related]
19. Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal.
Auriemma RS; Galdiero M; Grasso LF; Vitale P; Cozzolino A; Lombardi G; Colao A; Pivonello R
Eur J Endocrinol; 2010 May; 162(5):993-9. PubMed ID: 20156970
[TBL] [Abstract][Full Text] [Related]
20. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]